JMJD5 Inhibits Lung Cancer Progression by Regulating Glucose Metabolism Through the P53/tigar Pathway

Guiling Liu,Hongyan Qi,Jing Shen
DOI: https://doi.org/10.1007/s12032-023-02016-7
2023-01-01
Medical Oncology
Abstract:Abstract Metabolic reprogramming is considered one of the main driving forces for tumor progression, providing energy and substrates of biosynthesis to support rapid neoplastic proliferation. Particularly, the tumor suppressor protein p53 was shown to revert the Warburg effect and play complex roles in regulating glucose metabolism. Jumonji C domain-containing protein 5 (JMJD5) has previously been reported as a negative regulator of p53. However, the role of JMJD5 in p53-mediated metabolic reprogramming remains elusive. Here, we discovered that knockdown of JMJD5 significantly enhances TIGAR expression in p53 wild-type non-small cell lung cancer (NSCLC) cells, which could further suppress glycolysis and promote the pentose phosphate pathway. Besides, JMJD5 knockdown promotes the NSCLC cell proliferation in vitro and xenograft tumor growth in vivo, while silencing TIGAR can abolish this effect. Low expression levels of JMJD5 are correlated with increased levels of TIGAR and better prognosis of lung cancer patients. Taken together, our findings suggest that JMJD5 is a key regulator of tumor glucose metabolism by targeting the p53/TIGAR metabolic pathway.
What problem does this paper attempt to address?